A large-scale study in 59 HNSCC cell lines suggested that insulin receptor substrate 4 (IRS4) and SMAD4 mutations could predict sensitivity to CHK1/2 and WEE1 targeted agents [102]. Here, CHEK1 is linked to head and neck squamous cell carcinoma.